Therapeutic or comparative claims
Spot wording to secure, comparisons to document and passages that need regulatory or medical validation.
Pharma / ANSM
Review your pharma promotional materials before regulatory validation
EryonOne helps marketing, medical and regulatory teams spot sensitive passages in a healthcare asset before human arbitration, internal validation or submission.
Promotional materials
References provided
PDF only for now
French and English
Benefits
What EryonOne helps prepare
Consistency with references
Compare the asset with provided documents such as SmPC, MA, opinions or bibliography to identify discrepancies to examine.
Benefit / risk balance
Flag areas where benefits, limits, precautions or important mentions seem insufficiently visible.
Use cases
Use cases
- Pharmaceutical companies preparing an internal review.
- Healthcare agencies adapting content to the French market.
- International teams wanting to structure marketing, medical and regulatory exchanges.
Limits
An assistant, not a regulatory authorisation
EryonOne does not deliver any approval and does not amount to an authority sign-off. Regulatory, medical or legal leads keep the final say. The tool helps prepare, document and speed up a human review.
Frequently asked questions
FAQ
Does EryonOne deliver an ANSM approval?
No. EryonOne helps prepare the review of an asset, but replaces neither the competent authority nor internal regulatory validation.
Which promotional materials can be reviewed?
For now, priced review is on PDF. Detail aids, brochures, e-mailings, web pages, presentations, product sheets or scripts must therefore be provided as PDF; Word and PowerPoint come next.
Can the tool compare an asset with the SmPC or MA?
Yes, if the reference documents are provided. EryonOne helps spot discrepancies or points to arbitrate.
Who makes the final decision?
Regulatory, medical or legal teams always keep the final say.
Next step
Prepare a more structured review process
Share your asset, market and internal validation context to frame a first trial.